Can patiromer allow for intensified renin–angiotensin–aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD

INTRODUCTION: Chronic kidney disease (CKD) is associated with significantly increased morbidity and mortality. No specific treatment of the underlying condition is available for the majority of patients, but ACE-inhibitors (ACE-I) and angiotensin II-receptor blockers (ARB) slows progression in album...

Descripción completa

Detalles Bibliográficos
Autores principales: Mårup, Frederik Husum, Peters, Christian Daugaard, Christensen, Jeppe Hagstrup, Birn, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862471/
https://www.ncbi.nlm.nih.gov/pubmed/35190442
http://dx.doi.org/10.1136/bmjopen-2021-057503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862471/
https://www.ncbi.nlm.nih.gov/pubmed/35190442
http://dx.doi.org/10.1136/bmjopen-2021-057503

Ejemplares similares